Skip to content

Study · Animal study (in vivo) · mouse · 2015

2 results

Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.

Hopp K, Hommerding CJ, Wang X, Ye H, Harris PC, Torres VE

Journal of the American Society of Nephrology : JASN3 Jul 2014Cited by 101 (Europe PMC)

PMID24994926 (opens in a new tab)PMCIDPMC4279738 (opens in a new tab)DOI10.1681/asn.2013121312 (opens in a new tab)PepBankPUB-24994926
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Pkd1(RC/RC) mice, pasireotide alone markedly reduced cyst progression.

    In plain wordsIn mice with polycystic kidney disease, pasireotide alone reduced cyst progression.

    Peptide
    Pasireotide
    Outcome
    DecreaseCyst progression
    Study

    mousen: not reported in source

    Pkd1(RC/RC) polycystic kidney disease
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 5 monthsAs given in this study (mouse).

    Source sentences

    Summary
    Treatment with tolvaptan or pasireotide alone markedly reduced cyst progression and in combination showed a clear additive effect.
    1 context sentence
    Summary · context
    Here, we tested the efficacy of these compounds individually and in combination in a hypomorphic PKD1 model, Pkd1(R3277C/R3277C) (Pkd1(RC/RC)), in a 5-month preclinical trial.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In Pkd1(RC/RC) mice, pasireotide corrected hepatic hypertrophy.

    In plain wordsIn mice with polycystic kidney disease, pasireotide corrected liver enlargement.

    Peptide
    Pasireotide
    Outcome
    DecreaseHepatic hypertrophy
    Study

    mousen: not reported in source

    Pkd1(RC/RC) polycystic kidney disease
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 5 monthsAs given in this study (mouse).

    Source sentences

    Summary
    We also showed that Pkd1(RC/RC) mice experience hepatic hypertrophy that can be corrected by pasireotide.
    1 context sentence
    Summary · context
    Here, we tested the efficacy of these compounds individually and in combination in a hypomorphic PKD1 model, Pkd1(R3277C/R3277C) (Pkd1(RC/RC)), in a 5-month preclinical trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.